Peter Hecht, Cyclerion CEO
Cyclerion board quickly nixes CEO Peter Hecht's unorthodox pitch for low cash reserves
It’s been less than two months since Cyclerion laid out a new R&D strategy around its lead drug in mitochondrial diseases, one that triggered the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
